Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump
Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…What is holding back apomorphine therapy for Parkinson’s disease? Identifying knowledge gaps amongst Thai neurological medical professionals
Objective: To assess the level of understanding about, and identify knowledge gaps in, apomorphine therapy amongst Thai neurological medical professionals. Background: Continuous subcutaneous apomorphine infusion…The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease
Objective: A clinical audit of apomorphine pumps – The Indian experience. Background: Continuous dopaminergic therapy remains crucial in the management of moderately advanced Parkinson’s disease…Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017
Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine
Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…Apomorphine induced hemolytic anemia: A case report and literature review
Objective: To present a case of apomorphine induced hemolytic anemia Background: Drug induced immune hemolytic anemia (DIIHA) is a potentially lethal adverse reaction; It has…Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes
Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To characterize the relationship between plasma apomorphine concentrations and QTc (QT interval corrected for heart rate) in patients with Parkinson’s disease (PD) and “OFF”…The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials
Objective: The objective of this study to evaluate the efficacy and safety of subcutaneous apomorphine for patients with Parkinson’s disease (PD). Background: Subcutaneous apomorphine has…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »